Variation in long-term antipsychotic polypharmacy and high-dose prescribing across physicians and hospitals.
|Title||Variation in long-term antipsychotic polypharmacy and high-dose prescribing across physicians and hospitals.|
|Publication Type||Journal Article|
|Year of Publication||2014|
|Authors||Latimer E, Naidu A, Moodie EEM, Clark RE, Malla A, Tamblyn R, Wynant W|
|Date Published||2014 Oct|
|Keywords||Adolescent, Adult, Aged, Antipsychotic Agents, Canada, Drug Prescriptions, Female, Hospitals, Humans, Male, Middle Aged, Polypharmacy, Practice Patterns, Physicians', Schizophrenia, Young Adult|
OBJECTIVES: This study had two aims: to measure the prevalence of long-term prescribing of high doses of antipsychotics and antipsychotic polypharmacy in a large Canadian province and to estimate the relative contributions of patient-, physician-, and hospital-level factors.METHODS: Government hospital discharge, physician, and pharmaceutical claims data were linked to identify individuals with schizophrenia who in 2004 had antipsychotics available to them for at least 11 months. Individuals on a high dose throughout that period, as well as individuals on multiple concurrent antipsychotics (polypharmacy), were identified. Logistic and generalized linear mixed models using patient-, physician-, and hospital-level predictors were estimated.RESULTS: Among the 12,150 individuals identified, 11.9% were on a high dose and 10.4% on antipsychotic polypharmacy continually, with 3.7% in both groups. After adjustment for potential confounders, analyses showed that systematic propensity for physicians to prescribe high doses accounted for 10.9% of the remaining unexplained variance, and physicians as a group who prescribed high doses across a hospital or psychiatry department accounted for 3.0%. For antipsychotic polypharmacy the corresponding percentages were 9.7% and 6.2%. Even after adjustment, the variation in high-dose prescribing and antipsychotic polypharmacy remained substantial.CONCLUSIONS: Long-term high-dose and antipsychotic polypharmacy prescribing appeared partly driven by some physicians' and some hospitals' propensities to prescribe in this way independently of patient characteristics. Given the weight of the evidence against high-dose prescribing and antipsychotic polypharmacy, measures addressed to physicians and hospitals most likely to prescribe high doses, antipsychotic polypharmacy, or both should be considered.
|Alternate Journal||Psychiatr Serv|